Clinical Trial

Validation of Virtual Reality Tests for the Assessment of Patients With Age-related Macular Degeneration as Clinical Endpoints

Study acronym: VIRETTA
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in industrialized countries and affects tens of millions of people worldwide, with a rapidly increasing prevalence. It causes irreversible central vision loss and significant difficulties in daily activities, impairing patients' quality of life and independence. Conventional clinical assessments, which focus on visual acuity and retinal imaging, do not fully reflect the functional impact of the disease. Virtual reality (VR) makes it possible to create immersive, controlled environments to accurately measure functional vision and simulate real-life situations. The study proposes to develop a standardized and reproducible functional test in virtual reality that can complement conventional examinations and support clinical and industrial research.
Trial Details
NCT Number NCT07433088
Lead Sponsor Streetlab
Collaborators: CIL - Centre Ophtalmologique d'Imagerie et de Laser, Fondation Ophtalmologique Adolphe de Rothschild
Conditions Dry AMD, Geographic Atrophy, Healhty
Enrollment 60 participants
Start Date 2026-04
Primary Completion 2027-04 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2026-02-25